PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20722995-1	2010	OBJECTIVES: In rats with diabetes mellitus induced by alloxan (DMIA) or streptozocin (DMIS), changes in the cytochrome P450 (CYP) isozymes in the liver, lung, kidney, intestine, brain, and testis have been reported based on Western blot analysis, Northern blot analysis, and various enzyme activities.	Desipramine	86-90	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	108-123	
20722995-1	2010	OBJECTIVES: In rats with diabetes mellitus induced by alloxan (DMIA) or streptozocin (DMIS), changes in the cytochrome P450 (CYP) isozymes in the liver, lung, kidney, intestine, brain, and testis have been reported based on Western blot analysis, Northern blot analysis, and various enzyme activities.	Desipramine	86-90	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	125-128	
14555335-9	2003	The secondary amines nisoxetine (NIS), and especially, desipramine (DES) and nortriptyline (NOR), also inhibited CYP2C11 and generated MI complexes with microsomal CYP.	Desipramine	55-66	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	113-116	
14555335-9	2003	The secondary amines nisoxetine (NIS), and especially, desipramine (DES) and nortriptyline (NOR), also inhibited CYP2C11 and generated MI complexes with microsomal CYP.	Desipramine	68-71	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	113-116	
3225754-7	1988	These data strongly suggest that the hydroxylation pathways of imipramine and desipramine and the demethylation pathways of imipramine and 2-hydroxyimipramine are each sharing the same species of cytochrome P-450.	Desipramine	78-89	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	196-212	
10718121-2	2000	The formation of metabolite intermediate (MI)-complexes between cytochrome P450 (CYP) and the alkylamine-substituted drugs diltiazem (DTZ) and desipramine (DES) and their effect on CYP activities was investigated in rat liver.	Desipramine	143-154	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	64-79	
10718121-2	2000	The formation of metabolite intermediate (MI)-complexes between cytochrome P450 (CYP) and the alkylamine-substituted drugs diltiazem (DTZ) and desipramine (DES) and their effect on CYP activities was investigated in rat liver.	Desipramine	143-154	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	81-84	
10718121-2	2000	The formation of metabolite intermediate (MI)-complexes between cytochrome P450 (CYP) and the alkylamine-substituted drugs diltiazem (DTZ) and desipramine (DES) and their effect on CYP activities was investigated in rat liver.	Desipramine	156-159	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	64-79	
10718121-2	2000	The formation of metabolite intermediate (MI)-complexes between cytochrome P450 (CYP) and the alkylamine-substituted drugs diltiazem (DTZ) and desipramine (DES) and their effect on CYP activities was investigated in rat liver.	Desipramine	156-159	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	81-84	
10718121-2	2000	The formation of metabolite intermediate (MI)-complexes between cytochrome P450 (CYP) and the alkylamine-substituted drugs diltiazem (DTZ) and desipramine (DES) and their effect on CYP activities was investigated in rat liver.	Desipramine	156-159	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	181-184	
10718121-10	2000	By comparison, inhibition of CYP activity by DES was less pronounced than in control liver.	Desipramine	45-48	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	29-32	
10408227-7	1999	SKF 525-A, an inhibitor of cytochrome P450 (CYP), markedly suppressed DMI formation at both pH points.	Desipramine	70-73	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	27-42	
10408227-7	1999	SKF 525-A, an inhibitor of cytochrome P450 (CYP), markedly suppressed DMI formation at both pH points.	Desipramine	70-73	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	44-47	
10408227-9	1999	These results suggest that CYP enzyme(s) are mainly responsible for DMI formation at pH 8.5 and 7.5, and FMO enzyme(s) also are involved in IMI N-demethylation at a higher pH range in rat liver microsomes, at least in part.	Desipramine	68-71	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	27-30	
7090425-3	1982	The enzyme system involved was dependent on cytochrome P-450 and the main metabolites were desmethylimipramine (DMI), formaldehyde and p-chlorobenzoic acid.	Desipramine	91-110	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	44-60	
2872321-3	1986	Prolonged administration of desipramine and citalopram, but not amitriptyline, elevated the microsomal level of cytochrome P-450 and accelerated the rate of ethylmorphine demethylation.	Desipramine	28-39	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	112-128	
7090425-3	1982	The enzyme system involved was dependent on cytochrome P-450 and the main metabolites were desmethylimipramine (DMI), formaldehyde and p-chlorobenzoic acid.	Desipramine	112-115	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	44-60	
5314401-0	1970	Binding to cytochrome P-450 and metabolism of desmethylimipramine and metabolites in rat liver microsomes.	Desipramine	46-65	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	11-27	
5067380-0	1972	Oxidation and glucuronidation of certain drugs in various subcellular fractions of rat liver: binding of desmethylimipramine and hexobarbital to cytochrome P-450 and oxidation and glucuronidation of desmethylimipramine, aminopyrine, p-nitrophenol and 1-naphthol.	Desipramine	105-124	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	145-161